Galvani Bioelectronics

Galvani Bioelectronics is a Stevenage, United Kingdom-based bioelectronics R&D company. 
History.
It was founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016. The partnership to form the company was announced on 1 August 2016.
Verily has a 45% equity interest, while GSK has a 55% equity interest, making GSK the effective owner. The initial agreed upon investment between the two companies is up to £540 million over a period of seven years and will be used "to develop prototype devices aimed at controlling a variety of chronic conditions." Additionally, both companies agreed to contribute their existing intellectual property rights.